Eli Lilly and Co. (LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. said Jentadueto tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.
JENTADUETO is a new prescription medication for patients who need to control their blood sugar. Taken twice daily, it combines two diabetes medicines, the dipeptidyl peptidase-4 inhibitor, linagliptin, and metformin, in one tablet.
JENTADUETO provides physicians with options to adjust the metformin dosing based on effectiveness and tolerability. It is available in three dosage strengths, taken twice daily: 2.5 mg linagliptin/500 mg metformin hydrochloride; 2.5 mg linagliptin/850 mg metformin hydrochloride; and 2.5 mg linagliptin/1000 mg metformin hydrochloride.
"By combining two important diabetes medicines in a single tablet, JENTADUETO provides people with type 2 diabetes another option to control their blood sugar," said David Pass, PharmD, vice president, cardiovascular and metabolic disorders marketing, Boehringer Ingelheim Pharmaceuticals, Inc.
"Making JENTADUETO available quickly following its approval further demonstrates Boehringer Ingelheim and Lilly's shared commitment to address the needs of the millions of Americans living with type 2 diabetes."
For comments and feedback: editorial@rttnews.com